AMSTERDAM, the Netherlands – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and...
Latest News
Gdańsk, Poland – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has published data in International Immunopharmacology which suggest that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset Type-1 diabetes (T1D) patients,...
Gdańsk, Poland – PolTREG S.A., a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide range of autoimmune diseases, announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 diabetes...
Ottawa, Canada – A new review in CMAJ (Canadian Medical Association Journal) is aimed at helping clinicians diagnose and manage polycystic ovarian syndrome (PCOS), an endocrine disorder that affects about 10% of females. This disorder affects females of reproductive age and is associated with infertility, miscarriage and pregnancy complications. Its...
Barcelona, Spain – International research led by the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University, in collaboration with Hospital del Mar, Hospital Clínic, Charité – Medical University of Berlin, and the universities of Oslo and Genoa, has developed a computational biology tool, based on multi-level network...
SOUTH SAN FRANCISCO, Calif. — Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its Phase 2 clinical trial of picoplatin in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The data demonstrate that picoplatin in combination with...
LONDON, UK – Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel...
INGELHEIM AM RHEIN, Germany – Boehringer Ingelheim today announced new data from the global Phase III FIBRONEER™ program on nerandomilast, an investigational oral preferential PDE4B inhibitor, which is currently not approved for use. The new pooled analyses, the first to demonstrate a nominally significant reduction in risk of death across...
SEOUL, South Korea – A research team at the Yonsei University College of Medicine reported in Seminars in Arthritis & Rheumatism that poor physical function at baseline is associated with premature death in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA)—2 conditions that fall under the umbrella of...
GAINESVILLE, Fla. — The idea that anti-inflammatory drugs might protect people struggling with dementia from Alzheimer’s disease has received a blow with the online release of a study of human brain tissue in Acta Neuropathologica. Researchers with the McKnight Brain Institute of the University of Florida, in collaboration with scientists...